Pharmacological and Parenteral TherapiesQuestion 1196 of 2368
Which infant is a candidate for palivizumab?
- A 10-month-old who was born prematurely
- A healthy full-term 18-month-old
- A healthy 4-year-old with a mild cold
- A healthy full-term 3-month-old
Show answer
Correct answer: A 10-month-old who was born prematurely
Palivizumab is recommended for children under 24 months who were born premature or have chronic heart, lung, or neuromuscular disease.
Source: Nursing Health Promotion (Open RN, Chippewa Valley Technical College, 2025), Childhood Respiratory Disorders: Implementation (Take Action). Licensed under CC BY 4.0.
Practice the topic "Pharmacological and Parenteral Therapies"Questions last reviewed: 18 October 2026